Overview

The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.

Participants in this study with existing Enterra® devices will be randomly assigned to one of three programming methods that will be active during sleep. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at study visits.

Participants will be involved in the study for up to six months after treatment assignment.

Programming parameters in the study are within currently approved labeling.

Eligibility

In order to be eligible to participate in this study, a participant must meet all of the

following criteria:

1. Completed informed consent process with signed and dated informed consent form;
2. Stated willingness to comply with all study procedures and availability for the duration of the study;
3. Male or female, aged ≥18 or ≤70 at time of informed consent;
4. Currently implanted with the Enterra® Therapy System (Enterra® II 37800 neurostimulator);
5. High GES output defined as remaining pulse generator expected life of > 9 months from enrollment and less than 4 years from the time of implant;
6. Stable gastroparesis symptoms, in the opinion of the investigator;
7. On stable medical therapy for gastroparesis symptoms;
8. On stable supplemental nutritional support during the month prior to enrollment;
9. English language comprehension to complete study-required assessments;
10. Reliable access to internet-connected smart device(s) to complete study-required assessments.

        A participant who meets any of the following criteria will be excluded from participation
        in this study:
          1. Post-surgical gastroparesis (e.g., fundoplication, Bilroth I or II) or other active
             stomach or gastrointestinal diseases disorders which could explain symptoms in the
             opinion of the investigator;
          2. Subjects, in the opinion of the investigator, with profound nausea and/or vomiting at
             night;
          3. Subjects, in the opinion of the investigator, with profound gastroparesis symptoms
             upon waking in the morning;
          4. Subjects without a regular and defined sleep schedule;
          5. Pregnancy, or subject that intends to become pregnant during participation in the
             study;
          6. Chemical dependency;
          7. Enterra lead impedance measurements ≥ 700 Ohms at screening visit;
          8. Life expectancy < 1 year from conditions other than GI diseases;
          9. Subjects with an underlying disease leading to follow-up by MRI outside of current MR
             conditional indications;
         10. Participation in other clinical studies;
         11. Subjects involved in current or past medical-related litigation;
         12. Subjects with cognitive impairment or other characteristic that would limit subject's
             ability to complete study requirements.